Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Digestive System Diseases

Rare Diseases

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Uterine Cervical Neoplasms

Glioblastoma

Head and Neck Neoplasms

Anus Neoplasms

Carcinoma

Uterine Cervical Dysplasia

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Endocrine Gland Neoplasms

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Endocrine System Diseases

Gonadal Disorders

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Astrocytoma

Glioma

Neoplasms, Neuroepithelial

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms, Nerve Tissue

Uterine Neoplasms

Uterine Cervical Diseases

Uterine Diseases

Rectal Neoplasms

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Intestinal Diseases

Anus Diseases

Rectal Diseases

Precancerous Conditions

Ovarian Cancer

Ovarian Epithelial Cancer

Cervical Intraepithelial Neoplasia

Anal Cancer

Neuroepithelioma

Patient receiving an anticancer treatment in the context of their standard care.

Blood samples, tumor biopsy specimens and ascites samples will be collected at different time points (if feasible, according to the samples taken in the standard practice):

* at Baseline.
* at every surgical procedure or tumor biopsy.
* every 6 months (± 2 months) (only blood sample).
* at the time of the progression or recurrence, if applicable.

For patients undergoing a RT treatment, blood samples will be collected before the RT (i.e. at the time of planning CT-scan), at the last session of RT (± 2 days) and 3 months after the end of the RT (± 2 weeks).

Blood samples, tumor biopsy specimens and ascites samples will be collected.

Alejandra MARTINEZ

Julien MAZIERES

Rosine GUIMBAUD

This trial is a translational, open-label, multicentric, prospective cohort study of 900 patients aiming to describe the PD-1 (programmed death) expression in T cells (T lymphocytes) in different solid tumors.

The study will be conducted on a population of patients with local and/or metastatic malignant solid tumor and who are followed within a standard of care procedure or clinical trial.

Patients with any of the following tumor types may be enrolled in the trial:

* Head and neck cancer,
* Ovarian cancer,
* Cervical cancer,
* Pre-invasive CIN III cervical cancer (Cervical Intra-epithelial Neoplasia III cervical cancer),
* Other solid tumor types (including glioblastoma, NSCLC (Non-small cell lung cancer), anal cancer)

Each tumor type will be considered as an independent cohort.

For each included patient, biological specimen (tumor sample, blood samples and ascites samples if applicable) will be collected.

Study participation of each patient will be 5 years.

Deciphering Mechanisms Underlying Cancer Immunogenicity

Institut Claudius Regaud

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Deciphering Mechanisms Underlying Cancer Immunogenicity	NCT03958240	Head and Neck C... Ovarian Cancer Cervical Cancer Cervical Intrae... Glioblastoma Mu... Non Small Cell ... Anal Cancer	Blood samples, ...	18 Years -	Institut Claudius Regaud
Deciphering Mechanisms Underlying Cancer Immunogenicity	NCT03958240	Head and Neck C... Ovarian Cancer Cervical Cancer Cervical Intrae... Glioblastoma Mu... Non Small Cell ... Anal Cancer	Blood samples, ...	18 Years -	Institut Claudius Regaud

Spots Global Cancer Trial Database for glioblastoma multiforme of brain stem